The Sunrest Lifescience date has been confirmed from November 7 and ended on November 9
Sunrest Lifescience is involved in the domestic marketing of OTC generic pharmaceutical goods. Sunrest Lifescience distributes a variety of pharmaceutical medicines made by outside producers. The corporation is present in these states through goods that are registered trademarks or that are pending registration.
Start your investing journey today. How do you open your own demat account for free?
Bidding Dates
November 7 – 9
Price Range
₹84 per share
Face Value
₹10 per share
GMP
₹5
Sunrest Lifescience GMP
The Sunrest Lifescience IPO GMP is ₹[5].
IPO Overview
Sunrest Lifescience was listed on the stock exchange on 20-11-2023. The IPO was subscribed 48.54x. The last GMP for Sunrest Lifescience IPO was ₹5, updated on Nov 20th 2023 09:30 AM. As per the last GMP, the expected profit/loss for the IPO was 5.95%. The issue price of Sunrest Lifescience IPO (SUNREST) was ₹84.00, listed at a price of ₹84, which is 0.00% exactly match the allotment price. The expected IPO listing price as per grey market was ₹89, listed below GMP price and marked as negative listing for GMP.
Sunrest Lifescience IPO Details
| Sunrest Lifescience IPO Dates | 7 – 9 November 2023 |
| Sunrest Lifescience Issue Price | INR 84 per share |
| Fresh issue | 1,291,200 shares (INR 10.85 crore) |
| Offer For Sale | Nil |
| Total IPO size | 1,291,200 shares (INR 10.85 crore) |
| Minimum bid (lot size) | 1,600 shares (INR 134,400) |
| Face Value | INR 10 per share |
| Retail Allocation | 50% |
| Listing On | NSE SME |
Sunrest Lifescience Financial Performance
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | |
| Revenue | 16.95 | 26.89 | 24.64 | 5.64 |
| Expenses | 16.72 | 25.86 | 21.93 | 4.66 |
| Net income | 0.17 | 0.78 | 2.04 | 0.75 |
Sunrest Lifescience Valuations & Margins
| FY 2021 | FY 2022 | FY 2023 | |
| EPS | 0.55 | 2.59 | 6.81 |
| PE ratio | – | – | 12.33 |
| RONW (%) | 56.12 | 72.49 | 65.59 |
| NAV | 10.38 | ||
| EBITDA (%) | 1.62 | 4.17 | 11.89 |
| Debt/Equity | 7.72 | 2.88 | 0.64 |
Sunrest Lifescience IPO Dates & Listing Performance
| IPO Opening Date | 7 November 2023 |
| IPO Closing Date | 9 November 2023 |
| Finalization of Basis of Allotment | 15 November 2023 |
| Initiation of refunds | 16 November 2023 |
| Transfer of shares to demat accounts | 17 November 2023 |
| IPO Listing Date | 20 November 2023 |
| Opening Price on NSE SME | Coming soon |
| Closing Price on NSE SME | Coming soon |
Company Profile
Sunrest Lifescience offers a range of products, including tablets, capsules, syrups, ointments, gels, mouthwash, suspensions, dry powders, and toothpaste. A variety of medications, including Dental Cure, Anti Protozol, Anti Histamine, Anti-Hypertensive, Anti-Diabetic, Anti-Bacterial, Anti-Diarrheal, Anti-Fungal, Anti-Malerial, Anti-Inflammatory, Cosmetic, Anti-Parasitic, Multivitamin, Multimineral, and Nutraceutical, are included in its product portfolio. The business has 32 product names covered by 18 registered trademarks.
Several outside manufacturers and one of its group companies support its commercial activities. Typically, Sunrest Lifescience interacts with pharmaceutical manufacturers via purchase orders or third-party manufacturing, depending on the customer’s needs.
Registrar Info
| Name | SKYLINE FINANCIAL SERVICES PRIVATE LIMITED |
| Phone number | +011 26812682 |
| Email ID | grievances@skylinerta.com |
| Website | https://www.skylinerta.com |
Contact Details
| Name | SUNREST LIFESCIENCE LIMITED |
| Phone number | 079 – 29918245 |
| Email ID | info@sunrestlifescience.com |
| Website | https://www.sunrestlifescience.com |
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
